Elevated Iron and Ferritin: Causes, Symptoms, and Treatment

Diagnostic Approach

When you encounter elevated ferritin and iron, immediately measure both serum ferritin AND transferrin saturation together—never rely on either marker alone, as ferritin is an acute-phase reactant that rises with inflammation, infection, malignancy, and liver disease, making it unreliable as a standalone test. 1, 2

Initial Laboratory Evaluation

Obtain transferrin saturation (calculated as serum iron/total iron binding capacity × 100) alongside serum ferritin as the first-line screening panel. 2, 3
Transferrin saturation >45% warrants further investigation for iron overload, while >55% specifically indicates increased risk for hereditary hemochromatosis. 2
Case-finding thresholds for hereditary hemochromatosis are: ferritin >200 µg/L in women or >300 µg/L in men COMBINED with transferrin saturation >55%. 2

Distinguishing True Iron Overload from Hyperferritinemia Without Overload

The key distinction depends on transferrin saturation:

High transferrin saturation (>45-55%) + elevated ferritin = true iron overload requiring genetic testing and imaging. 2, 4
Normal or low transferrin saturation + elevated ferritin = hyperferritinemia without iron overload, suggesting inflammation, excessive alcohol intake, liver disease, malignancy, or metabolic syndrome. 5, 4

Causes of Elevated Iron and Ferritin

Primary Iron Overload (High Transferrin Saturation)

Hereditary Hemochromatosis:

C282Y homozygosity accounts for approximately 90% of hereditary hemochromatosis cases, caused by inappropriately low hepcidin leading to excessive dietary iron absorption. 2, 5
C282Y/H63D compound heterozygosity can cause iron overload in a small proportion of individuals. 2
Ferroportin gene mutations cause autosomal dominant disease with generally moderate iron overload. 5

Secondary Iron Overload:

Thalassemia syndromes, myelodysplastic syndrome, myelofibrosis, sideroblastic anemias, sickle cell disease, or pyruvate kinase deficiency. 6
Transfusion-dependent anemias. 5
Chronic liver diseases. 6

Hyperferritinemia Without Iron Overload (Normal/Low Transferrin Saturation)

Dysmetabolic iron overload syndrome (DIOS) is the most common iron overload condition, defined by unexplained ferritin elevation with metabolic syndrome criteria and only mild hepatic iron increase on MRI. 5
Inflammation, infection, or rheumatologic conditions (adult-onset Still's disease, hemophagocytic lymphohistiocytosis). 1, 7
Malignancy (most frequent cause of markedly elevated ferritin in one large series). 7
Chronic liver disease, kidney failure. 6, 3
Excessive alcohol intake. 2, 5

Clinical Manifestations

Symptoms of Iron Overload

Untreated hereditary hemochromatosis progresses to severe organ damage:

Cirrhosis and hepatocellular carcinoma (cirrhosis accounts for roughly 75% of hemochromatosis-related deaths). 2
Type 2 diabetes mellitus ("bronze diabetes") from pancreatic β-cell iron deposition—largely irreversible even with treatment. 2
Cardiomyopathy and cardiac arrhythmias (the most common causes of sudden death in iron overload, especially during rapid iron mobilization). 2
Arthropathy, particularly metacarpophalangeal joints—irreversible and does not improve with phlebotomy. 2
Hypogonadism from testicular iron deposition. 2
Skin hyperpigmentation, malaise, fatigue, abdominal pain (these may improve with iron removal). 2

Prognostic Indicators

All-cause mortality rises markedly when transferrin saturation exceeds 55% (hazard ratio 1.60). 2
Non-cirrhotic patients have normal life expectancy with early treatment, whereas cirrhotic patients have markedly higher mortality despite adequate iron removal. 2
Serum aminotransferases lack negative predictive value; about 50% of cirrhotic patients have normal ALT/AST. 2

Definitive Diagnosis

Genetic Testing

After informed consent discussing risks of labeling, insurance discrimination, and psychological impact, order HFE genetic testing when transferrin saturation ≥45% and/or ferritin exceeds gender-specific thresholds. 2
Test initially for C282Y mutation (accounts for ≈90% of cases); consider C282Y/H63D compound heterozygosity in select cases. 2

Imaging: MRI R2* Relaxometry

MRI with confounder-corrected R2-based relaxometry is the gold-standard non-invasive test for detecting and quantifying iron overload in liver, pancreas, heart, spleen, and brain—it has eliminated the need for liver biopsy in most scenarios.* 1

R2 sequences provide the most accurate and reproducible quantification of tissue iron concentrations*, validated at both 1.5T and 3T. 1
A single MRI examination can simultaneously assess multiple organs, facilitating comprehensive disease staging. 1
Distinct patterns aid differential diagnosis: early hereditary hemochromatosis shows predominant hepatic iron with minimal splenic involvement, whereas ferroportin disease and transfusional overload display increased splenic iron. 1
Hepatic R2 correlates linearly with total body iron burden and predicts the number of therapeutic phlebotomies required.* 1
Ultrasound and CT provide little quantitative information and are not recommended. 1

When to Perform Liver Biopsy

Liver biopsy is indicated when serum ferritin >1,000 µg/L or liver enzymes are elevated, to assess for cirrhosis and quantify hepatic iron concentration. 2, 5
Patients with ferritin <1,000 µg/L and normal liver enzymes may proceed directly to therapeutic phlebotomy without biopsy. 2
Elastography is recommended to identify advanced hepatic fibrosis when ferritin exceeds 1,000 µg/L. 5

Treatment

Therapeutic Phlebotomy (First-Line for Hereditary Hemochromatosis)

Initiate weekly or bi-weekly therapeutic phlebotomy (≈500 mL blood removal) immediately after diagnosis—this is the cornerstone of treatment for hereditary hemochromatosis. 2

Protocol:

Obtain hematocrit/hemoglobin before each phlebotomy and ensure decline does not exceed 20% of baseline. 2
Re-check serum ferritin after every 10–12 phlebotomy sessions. 2
The therapeutic target is ferritin 50–100 µg/L; once achieved, maintenance phlebotomy at individualized intervals keeps ferritin within this range. 2, 5
Baseline hepatic R2* values forecast the number of phlebotomies required for iron removal. 1

Critical Precautions:

Avoid vitamin C supplements during phlebotomy because high-dose vitamin C accelerates iron mobilization beyond transferrin capacity, increasing pro-oxidant activity and cardiac risk. 2
In patients receiving iron chelators, limit vitamin C intake to ≤200 mg per day. 2
Avoid raw shellfish due to heightened risk of Vibrio vulnificus infection in iron-overloaded individuals. 2
Dietary iron restriction is unnecessary; phlebotomy removes approximately 250 mg of iron weekly, far exceeding the 2–4 mg/day reduction achievable by diet. 2
Obtain cardiac evaluation for cardiomyopathy and arrhythmias before starting phlebotomy, as cardiac complications are especially hazardous during initial iron mobilization. 2

Iron Chelation Therapy

Chelators are used in iron overload associated with anemia (myelodysplastic syndromes or transfusion-dependent thalassemia). 5

Initiate chelation when hepatic iron content exceeds 120 µmol/g. 5
Deferasirox is often used as first-line therapy, but deferiprone may be of interest despite hematological toxicity (neutropenia). 5
Deferoxamine (parenteral route) is the treatment of choice for severe iron overload or emergency conditions. 5

Management of Dysmetabolic Iron Overload Syndrome (DIOS)

Bloodlettings are often poorly tolerated in DIOS without clear benefit, as current evidence does not conclusively support phlebotomy in patients with metabolic syndrome or chronic liver disease despite elevated transferrin saturation. 2, 5

Irreversible vs. Potentially Reversible Manifestations

Irreversible features that do NOT respond to phlebotomy: arthropathy, hypogonadism, established cirrhosis, and diabetes (pancreatic β-cell damage does not improve; most patients require ongoing insulin therapy). 2
Features that often improve with iron removal: malaise/fatigue, skin hyperpigmentation, abdominal pain, and in some cases modest reduction in insulin requirements. 2

Surveillance and Long-Term Management

Hepatocellular Carcinoma (HCC) Screening

All cirrhotic patients should undergo regular HCC surveillance (imaging and α-fetoprotein), as the risk of HCC persists even after successful iron depletion in established cirrhosis. 2
HCC is exceedingly rare in non-cirrhotic hemochromatosis, supporting early detection and treatment before cirrhosis develops. 2

Liver Transplantation

Decompensated cirrhosis constitutes an indication for evaluation for orthotopic liver transplantation. 2
Post-transplant survival is comparable to other liver disease etiologies when adequate iron removal is achieved pre-operatively. 2

Common Pitfalls to Avoid

Do not rely on serum iron concentration alone for screening, because it has poor sensitivity and specificity. 2
Do not screen based solely on transferrin saturation or ferritin; both must be measured together for accurate case-finding. 2
Do not postpone phlebotomy while awaiting genetic confirmation if biochemical evidence of iron overload is present; early treatment prevents irreversible organ damage. 2
Do not omit liver biopsy when ferritin exceeds 1,000 µg/L, as detection of cirrhosis fundamentally alters prognosis and surveillance strategy. 2
Do not assume that diabetes will improve with iron removal; most patients will continue to need insulin therapy. 2
Do not allow rapid iron mobilization in patients with known cardiac involvement without close cardiac monitoring. 2
Do not assume all HFE mutations confer equal risk; the clinical significance of the H63D allele remains uncertain, and most compound heterozygotes never develop significant disease. 2

What are the causes, clinical manifestations, and management of elevated serum iron and ferritin levels?

Have a follow-up question?